Improving Cardiovascular Outcomes in Type 2 Diabetes with SGLT2 Inhibitors – What is the Role of the Cardiologist? | Diabetes on the Net

For healthcare professionals only

In association with the

For prescribing information UKIE

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

Monday 10 August 2020​

12.45pm – 2.00pm

6.45pm – 8.00pm

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim and Lilly Diabetes Alliance products will be discussed in this webcast.

Speakers

Professor Naveed Sattar

Professor of Metabolic Medicine, Institute of Cardiovascular & Medical Sciences, University of Glasgow; Honorary Consultant in Metabolic Medicine, Glasgow Royal Infirmary

Professor Martin Cowie

Professor of Cardiology, Health Services Research, Imperial College, University of London; Honorary Consultant, Royal Brompton and Harefield NHS Trust

Agenda

Webcast introduction

Professor Martin Cowie

Type 2 diabetes, cardiovascular outcomes and the role of SGLT2 inhibitors​

Professor Naveed Sattar​

  • Type 2 diabetes as a cardiovascular risk factor
  • Cardiovascular outcome trials for glucose-lowering drugs: overview of results for SGLT2 inhibitors and GLP-1 receptor agonists
  • EMPA-REG OUTCOME, the cardiovascular outcome trial for empagliflozin: trial design and key results
  • Potential mechanisms of cardiovascular risk reduction with SGLT2 inhibitors

Putting the evidence into practice: does the cardiologist have an expanded role in the treatment of type 2 diabetes?

Professor Martin Cowie​

  • Prevalence of type 2 diabetes among patients with cardiovascular disease
  • Updated guidance and recommendations: ESC guidelines and ADA/EASD consensus report
  • Practicalities of treatment with an SGLT2 inhibitor, including sick-day rules
  • ’What cardiologists need to do’ for their patients with type 2 diabetes

Live panel discussion

Professors Martin Cowie and Naveed Sattar

Live Q&A session

Closing comments

Jardiance is the most initiated SGLT2i inhibitor in the UK1*

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise2

  • As monotherapy when metformin is considered inappropriate due to intolerance
  • In addition to other medicinal products for the treatment of diabetes

Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.2

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)

Adverse events should be reported. Reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue 
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 2913960 Fax: +44 1344 742661
or by email: PV_local_UK_Ireland@boehringer-ingelheim.com
*

Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment

Reference
1. Data on File. IQVIA new patient opportunity data April 2019. Boehringer Ingelheim.
2. Jardiance Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/28973 (accessed June 2020)
Days
Hours
Minutes
Seconds

In association with the

For prescribing information UKIE

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

Please complete the registration form

Your data is being collected by OmniaMed Communications on behalf of the Boehringer Ingelheim and Lilly Alliance solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and the Boehringer Ingelheim and Lilly Alliance.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
Adverse events should be reported. Reporting forms and information can be found at https://www.hpra.ie/homepage/ about-us/report-an-issue. Adverse events should also be reported to Boehringer-Ingelheim Drug Safety on 01 2913960, Fax: +44 1344 742661, or by e-mail: PV_local_UK_Ireland@ boehringer-ingelheim.com
The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable.
Boehringer Ingelheim and Lilly Diabetes Alliance products will be discussed in this webcast.
Marketing and organisational support has been provided by Omniamed Communications
Job code: PC-GB-101934 
Date of prep: June 2020

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.